In contrast, molecularly targeted therapies (e.g., EGFR, VEGFR, and FGFR inhibitors) and the incorporation of circulating tumor DNA (ctDNA) or next-generation sequencing remain investigational approaches, currently limited to clinical trials [62]. This evidence concerns the gene EGFR and neoplasm.